Abstract
8505 Background: ABVD plus radiation is standard therapy for limited HL, but carries risks of bleomycin-lung injury and radiation toxicity. Brentuximab vedotin is highly active in relapsed HL. We evaluated brentuximab plus AVD (A-AVD) for non-bulky stage I-II HL. Methods: This is a multicenter phase 2 study. Patients received a lead in cycle of brentuximab monotherapy 1.2mg/kg on days 1 and 15, followed by a PET scan. Patients then received 4-6 cycles of A-AVD, based on interim PETCT. The primary endpoint is complete response rate (CRR). A sample size of 34 was required to detect a CRR of 93% with 91% power and alpha error of 0.10. Results: 34 patients were enrolled. Median age is 36 (20–75). Risk was early favorable in 62%, unfavorable in 38%. The best CRR was 100%. After the monotherapy lead in, 18/34 subjects (53%) were in CR. After 2 cycles of A-AVD, 33 were in CR (97%), and 1 was removed for toxicity. At end of treatment (EOT), 30 (88%) were in CR, 2 were interpreted as progressive disease (PD), and ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
